Literature DB >> 17008081

Humanized mouse models for organ-specific autoimmune diseases.

Manuel A Friese1, Lise T Jensen, Nick Willcox, Lars Fugger.   

Abstract

Murine models for human autoimmune diseases are an essential tool for studying pathogenesis and for identifying new therapeutic targets. Mice are not the natural disease host, and conventional models have proved to be poor predictors of efficacy and safety in recent trials aiming to translate drug and biologic treatments to humans. Evidently, further steps towards recapitulating human diseases are urgently needed, for example using transgenic predisposing human HLA allele(s) plus T-cell receptor(s) implicated in a representative patient's autoimmune disease. The latest development - humanizing most of the immune system by transplanting human hematopoietic stem cells into severely immunodeficient mice - should lead to even better modeling.

Entities:  

Mesh:

Year:  2006        PMID: 17008081     DOI: 10.1016/j.coi.2006.09.003

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  10 in total

1.  Myelin-reactive type B T cells and T cells specific for low-affinity MHC-binding myelin peptides escape tolerance in HLA-DR transgenic mice.

Authors:  Kazuyuki Kawamura; Katherine A McLaughlin; Robert Weissert; Thomas G Forsthuber
Journal:  J Immunol       Date:  2008-09-01       Impact factor: 5.422

2.  Role of glycine N-methyltransferase in the regulation of T-cell responses in experimental autoimmune encephalomyelitis.

Authors:  Chung-Hsien Li; Ming-Hong Lin; Shih-Han Chu; Pang-Hsien Tu; Cheng-Chieh Fang; Chia-Hung Yen; Peir-In Liang; Jason C Huang; Yu-Chia Su; Huey-Kang Sytwu; Yi-Ming Arthur Chen
Journal:  Mol Med       Date:  2015-03-24       Impact factor: 6.354

3.  Humanized mouse models to study human diseases.

Authors:  Michael A Brehm; Leonard D Shultz; Dale L Greiner
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2010-04       Impact factor: 3.243

Review 4.  Technical challenges in using human induced pluripotent stem cells to model disease.

Authors:  Krishanu Saha; Rudolf Jaenisch
Journal:  Cell Stem Cell       Date:  2009-12-04       Impact factor: 24.633

Review 5.  Disease-modifying agents for multiple sclerosis: recent advances and future prospects.

Authors:  Til Menge; Martin S Weber; Bernhard Hemmer; Bernd C Kieseier; Hans-Christian von Büdingen; Clemens Warnke; Scott S Zamvil; Aaron Boster; Omar Khan; Hans-Peter Hartung; Olaf Stüve
Journal:  Drugs       Date:  2008       Impact factor: 9.546

6.  Sepsis-induced human lymphocyte apoptosis and cytokine production in "humanized" mice.

Authors:  Jacqueline Unsinger; Jacquelyn S McDonough; Leonard D Shultz; Thomas A Ferguson; Richard S Hotchkiss
Journal:  J Leukoc Biol       Date:  2009-04-15       Impact factor: 4.962

7.  HLA-A2-matched peripheral blood mononuclear cells from type 1 diabetic patients, but not nondiabetic donors, transfer insulitis to NOD-scid/γc(null)/HLA-A2 transgenic mice concurrent with the expansion of islet-specific CD8+ T cells.

Authors:  Fatima Whitfield-Larry; Ellen F Young; Garrick Talmage; Elizabeth Fudge; Anita Azam; Shipra Patel; Joseph Largay; Warren Byrd; John Buse; Ali S Calikoglu; Leonard D Shultz; Jeffrey A Frelinger
Journal:  Diabetes       Date:  2011-04-26       Impact factor: 9.461

8.  Interferon-Beta Therapy of Multiple Sclerosis Patients Improves the Responsiveness of T Cells for Immune Suppression by Regulatory T Cells.

Authors:  Bettina Trinschek; Felix Luessi; Catharina C Gross; Heinz Wiendl; Helmut Jonuleit
Journal:  Int J Mol Sci       Date:  2015-07-17       Impact factor: 5.923

Review 9.  The case for induced pluripotent stem cell-derived cardiomyocytes in pharmacological screening.

Authors:  Jaffar M Khan; Alexander R Lyon; Sian E Harding
Journal:  Br J Pharmacol       Date:  2013-05       Impact factor: 8.739

10.  Importance of human leukocyte antigen (HLA) class I and II alleles on the risk of multiple sclerosis.

Authors:  Jenny Link; Ingrid Kockum; Aslaug R Lorentzen; Benedicte A Lie; Elisabeth G Celius; Helga Westerlind; Marie Schaffer; Lars Alfredsson; Tomas Olsson; Boel Brynedal; Hanne F Harbo; Jan Hillert
Journal:  PLoS One       Date:  2012-05-07       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.